Rena Therapeutics is a venture company authorized by Tokyo Medical and Dental University (TMDU) in order to accelerate the Hetero Duplex Oligonucleotide (HDO) technology and drive commercialization of oligonucleotide drug. The HDO technology is invented by Professor Takanori Yokota of TMDU, Professor Satoshi Obika of Osaka University and others.<\/p>\n\n\n\n
Oligonucleotide drug has been expected as new modality for treating intractable diseases, however, issues such as instability in blood and side effects have been revealed and widely recognized. HDO is composed of double stranded DNA\/RNA with ligand molecules for proper drug delivery (Figure1), and it is strongly expected to overcome these issues.<\/p>\n\n\n\n
Evaluated the high possibility of HDO technology, Rena Therapeutics executed non-exclusive license agreements with Ionis Pharmaceuticals, Inc. which is global leading company in RNA-targeted drug discovery and development, and Takeda Pharmaceutical Company Limited. which is the largest Pharmaceutical company in Japan. Nippon Shokubai invested in Rena Therapeutics to support its R&D and promote relationship in June 2017.<\/p>\n\n\n\n
2.Purpose of transaction<\/strong><\/p>\n\n\n\n Nippon Shokubai is establishing the Health and Medical Business, focusing on the fields of oligonucleotide drug, peptide drug, and Drug Delivery System (DDS). Nippon Shokubai plans to develop the DDS technology of oligonucleotide drug through this acquisition. 3.Overview of transaction<\/strong><\/p>\n\n\n\n (1) Transfer of the shares About Seller<\/p>\n\n\n\n (2) Personnel transfers (Rena Therapeutics)<\/p>\n\n\n\n 4.Overview of Rena Therapeutics<\/strong><\/p>\n\n\n\n 5.Forecast<\/strong><\/p>\n\n\n\n In order to provide the patients oligonucleotide drug even one day earlier, Nippon Shokubai will maximize the synergies of acquisition and keep on working to establish and develop drug development support business.<\/p>\n\n\n
By means of not only active business support from Nippon Shokubai to Rena Therapeutics but also the cooperation with Rena Therapeutics, TMDU, and Osaka University, Nippon Shokubai will promote HDO technology to be practical. Nippon Shokubai tries to expand the contracted API manufacturing business acquiring new clients such as pharmaceutical companies as a result of manufacturing HDO structured API.<\/p>\n\n\n\n
Nippon Shokubai purchased 301,250 shares.<\/p>\n\n\n\n<\/td> Before<\/td> After<\/td><\/tr> Percentage<\/td> 26.7% of all issued shares<\/td> 91.3% of all issued shares<\/td><\/tr> Class and Number of shares<\/td> Class B preferred<\/td> 125,000 shares<\/td> Normal
Class A preferred
Class B preferred<\/td>80,000 shares
200,000 shares
146,250 shares<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nName<\/td> Class and Number of shares<\/td><\/tr> INCJ, Ltd.<\/td> Class A preferred 200,000 shares \/ Class B preferred 21,250 shares<\/td><\/tr> Individuals<\/td> Normal 80,000 shares<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n <\/td> Current<\/td> New<\/td><\/tr> Shuichi Toriya<\/td> Outside director<\/td> President & CEO<\/td><\/tr> Shoichi Iwamoto<\/td> Administration manager<\/td> Director<\/td><\/tr> Shingo Horimoto<\/td> –<\/td> Outside director<\/td><\/tr> Jun Sasaki<\/td> President & CEO<\/td> Director
(retirement date is the end of November 2019)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nName<\/td> Rena Therapeutics Inc.<\/td><\/tr> Head Office<\/td> Otemachi Financial City Grand Cube 3F, 1-9-2 Otemachi, Chiyoda-ku, Tokyo, Japan<\/td><\/tr> Activity<\/td> Manufacturing, Sales and R&D of oligonucleotide<\/td><\/tr> Capital<\/td> 100 million yen<\/td><\/tr> Established<\/td> January 15th, 2015<\/td><\/tr> Numbers of shares outstanding<\/td> 466,666 shares<\/td><\/tr> End of fiscal year<\/td> December 31st<\/td><\/tr> Employees<\/td> 10 (as of October 2019)<\/td><\/tr> Website<\/td> https:\/\/www.renatherapeutics.com\/?lang=en<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
![\"\"](\"https:\/\/www.shokubai.co.jp\/en\/wordpress\/wp-content\/uploads\/2023\/02\/Fig1.jpg\")